Circulating miRNAs as Novel Diagnostic Biomarkers in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis

Table 1

Characteristics of the included studies.

First author	Year	Country	MicroRNAs	Regulation mode	Disease	Sample size		Male N (%)	Diagnostic power
						Case	Control		Sen (%)	Spe (%)
Y. Tan	2014	China	miR-122-5p	Upregulated	NAFLD	152	90	195 (80.5)	93.4	46.7
Y. Tan	2014	China	miR-1290	Upregulated	NAFLD	152	90	195 (80.5)	58.6	65.6
Y. Tan	2014	China	miR-27b-3p	Upregulated	NAFLD	152	90	195 (80.5)	59.9	72.7
Y. Tan	2014	China	miR-192-5p	Upregulated	NAFLD	152	90	195 (80.5)	34.9	93.3
Y. Tan	2014	China	miR-148a-3p	Upregulated	NAFLD	152	90	195 (80.5)	69.1	41.1
Y. Tan	2014	China	miR-99a-5p	Upregulated	NAFLD	152	90	195 (80.5)	25.7	90
Y. Tan	2014	China	6miRs panel	Upregulated	NAFLD	152	90	195 (80.5)	90.3	76.2
N. C. Salvoza	2016	America	miR-34a	Upregulated	NAFLD	28	36	35 (54.7)	75	75
N. C. Salvoza	2016	America	miR-122	Upregulated	NAFLD	28	36	35 (54.7)	78.6	77.8
M. Celikbilek	2014	Turkey	miR-197	Downregulated	NASH	20	20	18 (45.0)	60	95
M. Celikbilek	2014	Turkey	miR-146b	Downregulated	NASH	20	20	18 (45.0)	55	100
M. Celikbilek	2014	Turkey	miR-181d	Downregulated	NASH	20	20	18 (45.0)	70	85
M. Celikbilek	2014	Turkey	miR-99a	Downregulated	NASH	20	20	18 (45.0)	65	95
X. L. Liu	2016	China	miR-34a	Upregulated	NASH	31	37	40 (58.8)	70.4	87.5
T. Auguet	2016	Spain	miR122	Upregulated	NAFLD	61	39	0 (0.0)	96.6	54, 7
K. Jampoka	2018	Thailand	miR-29a	Downregulated	NAFLD	58	34	—	60.37	82.35
K. Jampoka	2018	Thailand	miR-122	Upregulated	NAFLD	58	34	—	75	82.35

Sen: sensitivity; Spe: specificity.